Blood and Lymphatic Diseases
Non-neoplastic blood and lymphatic disorders include a range of conditions that affect blood components and lymphatic system function, such as anemia, coagulation disorders, platelet abnormalities, and myelodysplastic syndromes. These disorders are treated in a variety of ways, including medications, blood transfusions, and bone marrow transplantation. In recent years, significant progress has also been made in the development of drugs for these non-neoplastic hematologic and lymphatic disorders.
- Anemia: Anemia is a disease in which the number of red blood cells or the amount of hemoglobin in the blood is lower than normal. New drug development for the treatment of anemia has focused on drugs that stimulate red blood cell production, such as erythropoiesis-stimulating agents (ESAs). ESAs are used to treat anemia caused by chronic kidney disease by mimicking the action of endogenous erythropoietin, which promotes the production of red blood cells.
- Coagulation disorders: Coagulation disorders are diseases in which the blood clotting process is affected, such as hemophilia. In this area, the development of new drugs is focused on alternative therapies and gene therapy. For example, the development of recombinant clotting factors provides an effective alternative treatment for hemophiliacs. In addition, research is progressing in gene therapy aimed at treating clotting disorders by repairing or replacing defective genes.
- Platelet Abnormalities: Platelet abnormalities disorders include a decrease in platelet count or abnormal function, such as immune thrombocytopenic purpura (ITP). Newer drugs for the treatment of ITP, such as thrombopoietin receptor agonists (TPO-RAs), reduce the risk of bleeding by mimicking the action of thrombopoietin and increasing platelet production.
- Myelodysplastic syndromes: Myelodysplastic syndromes are a group of disorders in which bone marrow cells abnormally proliferate, which may lead to anemia, bleeding tendencies, and an increased risk of infection. Currently, new drug development for the treatment of these disorders includes immunomodulators and targeted therapeutic agents. For example, immunosuppressants such as cyclosporine and tacrolimus may be used to treat certain types of myelodysplastic syndromes.
Blood and Lymphatic Diseases Drug Targets
Blood and Lymphatic Diseases Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized human CD20 at 2 μg/ml can bind Anti-CD20 recombinant antibody (CSB-RA015007A1HU), the EC50 is 3.243-7.085 ng/mL
Human TNFSF13B protein Fc tag (CSB-MP897523HU1) captured on COOH chip can bind Human BCMA protein Fc tag (CSB-MP023974HU1) with an affinity constant of 39 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized CD22 at 2 μg/ml can bind Anti-CD22 rabbit monoclonal antibody, the EC50 of human CD22 protein is 4.034-4.800 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized CD33 at 2 μg/ml can bind Anti-CD33 rabbit monoclonal antibody, the EC50 of human CD33 protein is 4.289- 5.312 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized CD30 at 5 μg/ml can bind human CD30L (CSB-MP023996HU1c9), the EC50 is 14.96-20.25 ng/ml
